As you may be aware the planned date for review of the above guidance was April 2009.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

The Institute has carried out a search for information relevant to this appraisal, and has found that to the best of its knowledge, no new evidence has been published that would have a material effect on the original guidance.  However, we are aware of on-going research  to determine the effects of growth hormone replacement therapy on quality of life and cardiovascular risk in growth hormone deficient adults  which is due to report at the end of 2011/beginning of 2012.

Consequently we propose that the review of the original guidance be deferred until 2012 when results of trial are published to allow this research to be available to inform the review.

In order to be completely confident that this is appropriate, we are asking   consultees and commentators with an interest in this topic, to inform us of any evidence which would suggest that an earlier review would be beneficial.  We would particularly like to be made aware of timelines around on-going research, etc. which might affect the scheduling of this review should we go ahead with the proposal following this consultation. 

Please note all comments received will be published on the Institute’s website when a decision has been made.

• A full list of the organisations contacted for this review

May 2009